NEW YORK, March 15, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced that Kevin Buchi has joined its Board of Directors.
Since serving as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (Nasdaq: TEVA) in October 2011, Mr. Buchi has served as Corporate Vice President, Global Branded Products for Teva. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer and Chief Financial Officer before becoming Cephalon's CEO in December 2010.
Ivan Bergstein, MD, Stemline's Chief Executive Officer, said, "We are honored to welcome Mr. Buchi to our Board of Directors. Kevin's vast experience and proven track record of success in this industry will be a tremendous asset to Stemline moving forward."
Mr. Buchi commented, "I am delighted to join Stemline's Board of Directors. The management team has done an outstanding job building out a clinical stage pipeline in an innovative area of oncology. I look forward to working with them as they advance these programs into late stage development and potentially into the marketplace."
About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase I/II studies of advanced cancer patients. In a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. The Company's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs), as well as an OS benefit compared with historical data in Phase I/II trials of adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.
Mark Jacobson Associate Director, Business Development Stemline Therapeutics, Inc. 750 Lexington Avenue Sixth Floor New York, NY 10022 Tel: 646-502-2307 Email: firstname.lastname@example.org
SOURCE Stemline Therapeutics, Inc